Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

183 results about "Targeted Mutation" patented technology

A mutation created in a gene at a specific location. Targeted mutations are frequently generated in the laboratory to investigate the influence of inactivation of a particular gene product.

Targeted evolution system based on orthogonal bacteriophage RNA polymerase and application

The invention provides a targeted mutation system based on orthogonal bacteriophage RNA polymerase and an orthogonal transcription mutant. According to the orthogonal transcription mutants, phage RNA polymerase and deaminase are fused, and a large number of mutations can be rapidly and efficiently generated on a target gene. The bacteriophage RNA polymerase part of the orthogonal transcription mutants can specifically recognize corresponding promoters and transcribe downstream genes, and the deaminase part of the bacteriophage RNA polymerase part of the orthogonal transcription mutants can generate mutation in the transcription process. The optimized orthogonal transcription mutants can simultaneously generate mutation from C: G to T: A and mutation from A: T to G: C on a target gene. According to the method, mutation and screening can be carried out on target genes on plasmids or genomes or genes on metabolic pathways, the evolution efficiency of enzymes or other proteins can be greatly improved, and time and cost are saved.
Owner:TSINGHUA UNIVERSITY

Compounds targeting mutant of p53

Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions comprising the compounds, methods of preparing the compounds and the use in the manufacture of medicaments for preventing or treating a disease or condition related to p53 mutants.
Owner:JACOBIO PHARMACEUTICALS CO LTD

Allele-specific knockdown of gene expression

Described herein are methods of inhibiting an allele that contains a mutation in a cell (e.g., treating a subject with an allele that contains a mutation). The method includes delivering to the cell an antisense oligonucleotide that targets a variant allele that is in cis with the mutation (e.g., the mutation is a gain of function mutation or a dominant negative mutation), wherein the cell or subject is heterozygous for the target variant, and the antisense molecule is effective at knocking down expression the target variant allele (e.g., effective at preventing, treating, or ameliorating at least one symptom associated with the mutation). Also described herein are methods of haplotyping a cell or subject, and antisense oligonucleotides that target mutant superoxide dismutase 1 (SOD1) and other genes.
Owner:UNIV OF MASSACHUSETTS

Efficient transgene-free genome editing in plants in the t0 generation based on a co-editing strategy

Transgene-free genome editing of plants in T0 generation is highly desirable but challenging, especially in perennials and vegetatively propagated plants. Here is provided a co-editing strategy for generating transgene-free, gene-edited plants via Agrobacterium-mediated transient expression of cytosine base editor (CBE) / gRNA-Cas 12a / crRNA-GFP in plants. Specifically, CBE / gRNA was used to base edit the AES gene to confer resistance to herbicide chlorsulfuron as a selection marker, which has no negative effects on plant phenotypes; Casl2a / crRNA was used for editing genes(s) of interest; GFP was used for selecting transgene-free transformants. Using this approach, transgene- free genome-edited plants were efficiently generated for various genes (either individual or multiplex) in tomato, tobacco, potato, and citrus in the T0 generation. The biallelic / homozygous transgene-free mutation rates for target genes among herbicide-resistant transformants ranged from 8% to 50%. Whole genome sequencing further confirmed transgene-free and absence of off- target mutations in the edited plants. The co-editing strategy is efficient for generating transgene- free, genome-edited plants in the T0 generation, thus being a potent tool for plant genetic improvement.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Joint transfer assisted orthogonal targeted mutation evolution system

The invention discloses a conjugational transfer-assisted orthogonal targeted mutation evolution system, which comprises a donor strain and a receptor strain, a donor strain intracellular muter performs targeted mutation on a target sequence to obtain a mutation sequence, a non-self-transferable conjugational transfer functional plasmid is introduced into the donor strain, and a non-self-transferable conjugational transfer functional plasmid is introduced into the receptor strain. The mutant sequence is unidirectionally and horizontally transferred from a donor strain cell to a receptor strain cell, and the complete orthogonality of the mutants in the initial donor strain and the mutant sequence in the receptor strain is realized through the orthogonality between the donor strain and the receptor strain. The results of a sacB-sucrose reverse screening experiment show that the mutation frequency of an ortho-MutaT7 system reaches 2.96 * 10 <-2 > at 96 hours, which is 1840.9 times of the natural mutation frequency of the sacB in donor cells, and the ortho-MutaT7 system generates mutation of 12 basic group change types in a target sequence. The Ortho-MutaT7 system developed by the invention realizes mutation diversity and also has orthogonality, leakage mutation and off-target mutation of mutants in host cells are fully avoided, and a direct relationship between a mutation sequence and a phenotype is established.
Owner:TIANJIN UNIV

Kit for detecting human BRAF gene V600E and TERT gene promoter mutation

The invention provides a kit for detecting human BRAF gene V600E and TERT gene promoter mutation, and belongs to the technical field of biology. The kit comprises a primer, a probe, a 5 * PCR (Polymerase Chain Reaction)-Enhancer, a 10 * PCR Buffer, dNTP (Deoxyribonucleoside Triphosphate) Mix, MalTaq DNAPlyase, magnesium ions, DEPC (Diethylpyrocarbonate) water, a positive control and a negative control. According to the present invention, the ARMS-PCR detection technology is adopted to detect the specific gene mutation, and the target mutation site is identified by designing the specific primer and the probe, such that the detection specificity and the detection sensitivity are improved; by combining with a Taqman probe technology, the fluorescent signal change in the PCR amplification process can be monitored in real time, so that whether mutation of a BRAF V600E site, a TERT C228T site and a TERT C250T site exists or not is accurately judged; according to the method, pre-amplification of 15 cycles is adopted, then quantitative amplification of 30 cycles is adopted, and when the initial amount of the target DNA is very low, the copy number of the target DNA can be increased, so that the detection accuracy and sensitivity are further improved.
Owner:XIAN BRIGHT CORNING BIOMEDICAL CENT CO LTD

Flavin monooxygenase FMO mutant and application thereof in indigo production

The invention discloses a flavin monooxygenase FMO mutant and application thereof in indigo production, and belongs to the technical field of microbial engineering. Through rational design, directional mutation or random mutation, a mutant with catalytic efficiency several times higher than that of wild-type flavin monooxygenase is obtained, then the mutant is integrated into escherichia coli to obtain a recombinant strain capable of expressing the mutant, and the obtained recombinant strain not only can realize cyclic regeneration of cofactors, but also can be used for preparing the flavin monooxygenase. An expensive cofactor NADPH does not need to be additionally added, so that the effects of saving materials and reducing the production cost are achieved; the fermentation period can be shortened, and the yield of indigo blue is increased and reaches the g-level level. Therefore, the flavin monooxygenase mutant and the constructed recombinant bacteria have good application prospects in the field of indigo production, and large-scale industrial production of indigo is promoted.
Owner:HANGZHOU VIABLIFE BIOTECH CO LTD

T cell receptors targeting PIK3CA mutations and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

T cell receptors targeting PIK3ca mutations and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

An erythrocyte-specific antibody screening test kit and preparation method of this test kit

The invention relates to an erythrocyte specific antibody screening test kit expressing a single antigen from a target erythrocyte (RBC) antigen (RhD and RhCE as 2 different antigens derived from RBC and 45 or more antigens in total including some variants of these two antigens) and a preparation method of this test kit. Said antigens are transgenically produced and provide the clearest results compared to traditional methods of antibody screening. Field-targeted mutation process is applied during the preparation of the erythrocyte-specific antibody screening test kit subject to the invention.
Owner:DİA PRO TIBBİ ÜRÜNLER SANAYİ & TİCARET ANONİM ŞİRKETİ

Double crRNA-CRISPR-Cas13a system established by using ERASE test paper and used for on-site detection of rifampicin resistance of mycobacterium tuberculosis

The invention discloses a CRISPR-Cas13a (clustered regularly interspaced short palindromic repeats-CRISPR-Cas13a) double crRNA (ribonucleic acid) system which is established by using ERASE test paper and is used for detecting the rifampicin resistance of mycobacterium tuberculosis on site. The CRISPR-Cas13a double crRNA-system comprises a Cas13a protein and crRNA, or a complex formed by the Cas13a protein and the crRNA; the crRNA comprises an anchoring sequence and a guide sequence; the anchoring sequence is used for being combined with Cas13a protein; the guide sequence is used for targeting mutation target sequences of sites 531, 526, 516 and 513 in a mycobacterium tuberculosis drug-resistant gene rpoB gene; the target sequence of the mycobacterium tuberculosis is located at the 2317th site to the 2597th site of the rifampicin drug-resistant gene rpoB. On the basis of a CRSPR-Cas13a nucleic acid detection technology, result interpretation is performed through RAA amplification in combination with a line elimination method (ERASE) lateral flow chromatography test paper, and experiments prove that the kit can target high-frequency mutation sites of four rifampicin drug-resistant genotypes at the same time, has good detection sensitivity and specificity, and can be used for detecting the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes of the rifampicin drug-resistant genotypes. The method can realize rapid, efficient, simple and convenient detection of mycobacterium tuberculosis rifampicin drug-resistant nucleic acid, has a sensitivity of 10 copies / [mu] L, and has an important application value.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES +1

Organ-like drug resistance prediction method and device and storage medium

The invention discloses an organ-like drug resistance prediction method and device and a storage medium, and relates to the technical field of bioinformatics, and the method comprises the steps: S1, constructing an initial prediction model; s2, acquiring a training data set; s3, training an optimization prediction model; s4, acquiring related data of a to-be-predicted drug; s5, obtaining a prediction result of the drug resistance of the to-be-predicted drug; according to the method, the drug resistance of the organoid to the drug can be predicted more accurately. By fusing multi-dimensional features of gene mutation, target mutation and drug functional groups, the understanding and learning ability of the model to the drug resistance mechanism is enhanced, and the reliability of drug resistance prediction is improved. The method not only can accurately capture key information of influence of gene and target mutation on drug resistance, but also can highlight unique mutant genes of the organoid on drug resistance by comparing feature differences of the organoid and a common cell line, so that an efficient and accurate calculation framework is provided for drug resistance detection.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA

T cell receptor targeting SLC2A1 mutation, related biological material and preparation method thereof

The invention discloses a T cell receptor targeting SLC2A1 mutation as well as a related biological material and a preparation method thereof, and belongs to the field of immunology. The invention aims to solve the technical problem of how to better treat cancers or tumors caused by SLC2A1 gene mutation. Therefore, the invention provides a TCR for targeted recognition of an SLC2A1 mutant peptide fragment. A TCR alpha chain of the TCR comprises a CDR3 sequence of which the amino acid sequence is SEQ ID NO.4; and the TCR beta chain comprises a CDR3 sequence of which the amino acid sequence is SEQ ID NO.7. The TCR sequence targeting the SLC2A1 mutant peptide fragment is obtained through screening, then TCR-T cell drugs or protein drugs and nucleic acid drugs based on the TCR are constructed, target cells expressing the SLC2A1 mutant peptide fragment can be effectively cleared away, the method is beneficial exploration for precise immunotherapy of diseases, and the corresponding TCR sequence is reported for the first time.
Owner:深圳泽医细胞治疗集团有限公司

Test method, device and storage medium for stateful network protocol

This invention provides a testing method, device, and storage medium for stateful network protocols. First, it accurately identifies new state transition events based on the response feedback of the server under test. Then, it extracts corresponding client request message pairs from protocol interaction messages, and further segments them according to field location rules to obtain semantically independent field units. It then identifies differences between field units with the same name to generate candidate field groups, and filters out the candidate field set that truly triggers the state transition through testing. Finally, it performs structure-aware targeted mutations on the test seed based on the candidate field set to generate test cases. By accurately locating the core fields that trigger state transitions, it solves the technical problem of insufficient granularity in trigger condition analysis, making subsequent mutations in the testing process more targeted and effectively improving the accuracy and efficiency of state exploration in fuzzy testing of stateful protocols.
Owner:INSTITUTE OF INFORMATION ENGINEERING CHINESE ACADEMY OF SCIENCES

T cell receptors targeting PIK3ca mutations and uses thereof

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Inhibitor drug screening method for targeting KRAS G12D mutation based on machine learning

The invention discloses a machine learning-based inhibitor drug screening method for targeting KRAS G12D mutation, and the method is used for predicting the binding capacity of candidate small molecules and KRAS G12D protein targets by constructing an integrated graph neural network (GNN) and molecular feature embedded deep learning model. Compared with a traditional virtual screening method, the method has remarkable advantages in the aspects of improving the recognition capacity of KRAS G12D mutation specific small molecules and reducing the false positive rate and has high application potential and industrial transformation value, and molecular dynamics simulation results of screened compounds show that compared with existing KRAS G12D mutation targeted drugs in research, the method has the advantages that the application potential and industrial transformation value of the screened compounds are greatly improved, and the application prospect of the KRAS G12D mutation targeted drugs is widened. The screened compound has a more stable binding trend with targeting protein in MD simulation, is expected to become a new KRAS G12D targeting inhibitor, and provides new possibility for treating pancreatic cancer.
Owner:NANJING TECH UNIV

TCR targeting KIT D816Y mutation-derived neoantigens and its application

The present invention provides a TCR targeting a KIT D816Y mutation-derived neoantigen, a nucleic acid molecule comprising a nucleotide sequence encoding the TCR or a complementary sequence thereof, a vector containing the nucleic acid molecule, and a cell transduced with the nucleic acid molecule or the vector, as well as a pharmaceutical composition comprising the TCR, nucleic acid molecule, vector or cell as an active ingredient, and use of the TCR, nucleic acid molecule, vector, cell and pharmaceutical composition in detecting, preventing and / or treating cancers associated with KIT D816Y gene mutation-derived neoantigens.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Tcr targeting flt3 d835h mutation-derived neoantigen and application

The present application provides a TCR targeting a FLT3D835H mutation-derived neoantigen, a nucleic acid molecule comprising a nucleotide sequence encoding the TCR or a complementary sequence thereof, a vector containing the nucleic acid molecule, a cell transduced with the nucleic acid molecule or the vector, a pharmaceutical composition comprising the TCR, the nucleic acid molecule, the vector or the cell as an active ingredient, and use of the TCR, the nucleic acid molecule, the vector, the cell or the pharmaceutical composition in detection, prevention and / or treatment of a cancer related to a FLT3D835H gene mutation-derived neoantigen.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

A primer probe set and kit for detecting rifampicin-resistant gene of mycobacterium tuberculosis

The application provides a primer probe set and a kit for detecting a rifampicin-resistant gene of Mycobacterium tuberculosis, and belongs to the technical field of molecular biology detection.The primer probe set comprises RAA primers and qPCR primers targeting the rpoB gene, probe primers targeting the wild-type rpoB gene, and probe primers targeting the mutant rpoB gene.The application adopts the detection methods of RT-RAA and qPCR in sequence, and the above specific primer probe set can be combined to simultaneously and rapidly detect the 516, 526, 531 and 533 sites of the rpoB gene of Mycobacterium tuberculosis, has good specificity, and the detection sensitivity can reach 5 copies / ul, is 20 times higher than the sensitivity of qPCR (100 copies / ul), and has a 5% detection capability for heterogenic drug resistance mutation; the detection method can also greatly shorten the detection time.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Crystalline forms of a compound targeting p53 mutants and uses thereof

This invention provides a crystal form of compound 1, a salt thereof, and a crystal form of the salt thereof. This invention also relates to pharmaceutical compositions comprising the crystal form of compound 1 and the crystal form of a salt of compound 1. This invention further relates to methods of preparing and using these compositions. Compound 1
Owner:JACOBIO PHARMACEUTICALS CO LTD

T cell receptor targeting KRAS G12V mutant polypeptide and application thereof

The invention provides a T cell receptor targeting KRAS G12V mutant polypeptide and application of the T cell receptor. The T cell receptor molecule specifically targets KRAS G12V mutation, a CDR3 sequence of an alpha chain variable region of the T cell receptor molecule is a mutant containing CAIPPGGSGDKLTF (SEQ ID NO: 1) or SEQ ID NO: 1, and / or a CDR3 sequence of a beta chain variable region of the T cell receptor molecule is a mutant containing CASSQNNEQFF (SEQ ID NO: 2) or SEQ ID NO: 2. The invention also provides a nucleic acid molecule for coding the T cell receptor molecule, a multivalent complex and a dual-targeting protein molecule containing the T cell receptor molecule, a nucleic acid construct, a cell for expressing the T cell receptor molecule and the like.
Owner:IMMUXELL BIOTECH LTD

Method for detecting low-frequency gene mutation based on PNA-PCR combined Cas13a system and application

The invention belongs to the technical field of biology, and provides a method for detecting low-frequency gene mutation based on PNA-PCR combined with a Cas13a system and application of the method. According to the method, a target mutation sequence is enriched through PNA-mediated allele specific amplification, a Cas13a / crRNA system is used for carrying out high-specificity recognition and fluorescence signal amplification on an amplification product, and the high-frequency gene mutation is detected through the Cas13a / crRNA system. High-sensitivity detection of low-frequency gene mutation in plasma circulating tumor DNA (ctDNA) is achieved, and the lower detection limit can reach 0.1%-0.01% VAF. The invention solves the problems of insufficient sensitivity, complex operation, high cost or strong equipment dependence and the like in the prior art such as next-generation sequencing, digital PCR and the like during low-frequency mutation detection, and is suitable for noninvasive rapid screening and precise diagnosis and treatment of clinical tumor gene mutation.
Owner:HENAN CANCER HOSPITAL

Targeting mutant KRAS with a mutation specific iga

PendingUS20250122308A1HydrolasesImmunoglobulins against animals/humansDimerImmunoglobulin monomer
Disclosed herein are dimeric or pentameric antigen binding molecules and methods for making said dimeric or pentameric antigen binding molecules, wherein the isotype of the immunoglobulin monomers is IgA, 1gG4, or IgM. Also disclosed herein are methods of using dimeric antigen binding molecules to treat cancer associated with expression of an oncogene, gene overexpression, or a gene fusion.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Gene mutation detection method and apparatus, device, medium, and product

Provided are a gene mutation detection method and apparatus, a device, a medium, and a product. The method includes acquiring a suspected mutation site of a nucleic acid sample under test, where the suspected mutation site is determined based on first mutation feature data generated by a first mutation detection module upon mutation calling performed on sequencing data of the nucleic acid sample under test, and the recall at which the first mutation detection module identifies gene mutation sites is greater than or equal to a preset recall; acquiring second mutation feature data and third mutation feature data of each suspected mutation site; and inputting the second mutation feature data and the third mutation feature data into a pre-trained target mutation detection model and outputting a mutation detection result of each suspected mutation site.
Owner:GENEMIND BIOSCIENCES CO LTD

AAV gene therapy for alpha-1 antitrypsin deficiency

PCT designated stage expiredWO2025034601A1Organic active ingredientsPolymorphism usesMedicineGenetics
The present disclosure relates to gene therapy for treating Alpha-1 antitrypsin deficiency (A1AD). Provided here are multifunctional AAV vectors that simultaneously deliver an RNAi molecule targeting a mutant AAT allele (e.g., the PiZ allele) and a normal AAT gene (e.g., the PiM allele). Also provided here are variant bovine AAV (BAAV) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce macrophages.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC +1

Inhibition of unintended mutations in gene editing

Provided are a fusion protein useful for performing base editing, a method for performing gene editing in a cell at a target site, a dual guide RNA system, and a guide RNA.SOLUTION: To provide fusion proteins and related molecules useful for performing base editing with reduced or no off-target mutations. The fusion protein can comprise a first fragment comprising a nucleobase deaminase or a catalytic domain thereof, a second fragment comprising a nucleobase deaminase inhibitor, and a protease cleavage site between the first fragment and the second fragment. Also provided are improved prime editing systems comprising prime editing guide RNAs with improved stability.SELECTED DRAWING: None
Owner:SHANGHAI TECH UNIV

Targeted mutant interferon-gamma and uses thereof

The present invention relates, in part, to chimeric proteins comprising a modified human IFN-γ having one or more mutations that confer reduced affinity and / or biological activity that is restorable by attachment to one or more targeting moieties. The one or more targeting moieties may have recognition domains which specifically bind to antigens or receptors of a tumor or an immune cell. The one or more recognition domains may be a single-domain antibody or a single-chain antibody (scFv). The application also provides use of the chimeric proteins as therapeutic agents.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2